unknown
Stage
About
Intervacc AB is a Swedish biotechnology company that develops recombinant protein fusion–based vaccines for animal health, including Strangvac® for equine strangles. The group includes subsidiaries Nordvacc Läkemedel and Mybac-Vettech and operates a sales organization active on the European animal health market.
Explore Intervacc AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.